Arcus Biosciences, Inc. (RCUS)
- Previous Close
15.50 - Open
15.49 - Bid 15.37 x 1000
- Ask 16.15 x 900
- Day's Range
14.73 - 15.85 - 52 Week Range
12.95 - 25.47 - Volume
524,078 - Avg. Volume
824,108 - Market Cap (intraday)
1.402B - Beta (5Y Monthly) 0.85
- PE Ratio (TTM)
-- - EPS (TTM)
-4.15 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.20
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
www.arcusbio.comRecent News: RCUS
Performance Overview: RCUS
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RCUS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RCUS
Valuation Measures
Market Cap
1.41B
Enterprise Value
660.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.80
Price/Book (mrq)
3.05
Enterprise Value/Revenue
5.64
Enterprise Value/EBITDA
-2.27
Financial Highlights
Profitability and Income Statement
Profit Margin
-262.39%
Return on Assets (ttm)
-17.42%
Return on Equity (ttm)
-54.87%
Revenue (ttm)
117M
Net Income Avi to Common (ttm)
-307M
Diluted EPS (ttm)
-4.15
Balance Sheet and Cash Flow
Total Cash (mrq)
759M
Total Debt/Equity (mrq)
26.19%
Levered Free Cash Flow (ttm)
-187.75M
Research Analysis: RCUS
Company Insights: RCUS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RCUS
RCUS: Lowering target price to $16.00
ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $16.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
RatingPrice TargetRCUS: Lowering target price to $17.00
ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $17.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRCUS: Raising target price to $18.00
ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRCUS: Rating increased to a HOLD
ARCUS BIOSCIENCES INC has an Investment Rating of HOLD; a target price of $14.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target